問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of Pediatrics

Kaohsiung Municipal Ta-Tung Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

卓士峰Cho, Shih-Feng
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

58Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

卓士峰

List

85Cases

2022-07-01 - 2027-07-31

Phase III

Active
A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    Pozelimab Cemdisiran Ravulizumab Eculizumab

Participate Sites
9Sites

Not yet recruiting9Sites

2023-03-01 - 2028-10-16

Phase III

Active
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    PozelimabCemdisiran

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2022-01-14 - 2026-07-31

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-11-27 - 2022-03-31

Phase I/II

Completed
A Phase 1/2 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia / FLT3-mutated Acute Myeloid Leukemia

  • Test Drug

    Gilteritinib (ASP2215)

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-10-31 - 2029-02-28

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-05-01 - 2028-12-22

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-09-01 - 2025-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-12-10 - 2028-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2021-10-01 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-06-01 - 2028-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB